Alzheimer's disease

被引:1343
作者
Masters, Colin L. [1 ]
Bateman, Randall [2 ]
Blennow, Kaj [3 ]
Rowe, Christopher C. [4 ]
Sperling, Reisa A. [5 ,6 ]
Cummings, Jeffrey L. [7 ]
机构
[1] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, 30 Royal Parade, Parkville, Vic 3010, Australia
[2] Washington Univ, Sch Med, St Louis, MO USA
[3] Univ Gothenburg, Sahlgrenska Univ Hosp, Dept Neurosci & Physiol, Clin Neurochem Lab, Gothenburg, Sweden
[4] Austin Hlth, Mol Imaging Res, Melbourne, Vic, Australia
[5] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA
[6] Massachusetts Gen Hosp, Memory Disorders Unit, Boston, MA 02114 USA
[7] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Las Vegas, NV USA
关键词
QUALITY-OF-LIFE; MILD COGNITIVE IMPAIRMENT; PHOSPHORYLATED TAU-PROTEIN; AMYLOID-BETA DEPOSITION; AGE-SPECIFIC INCIDENCE; CEREBROSPINAL-FLUID; APOLIPOPROTEIN-E; A-BETA; IN-VIVO; PARKINSONS-DISEASE;
D O I
10.1038/nrdp.2015.56
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Alzheimer's disease is a chronic illness with long preclinical and prodromal phases (20 years) and an average clinical duration of 8-10 years. The disease has an estimated prevalence of 10-30% in the population >65 years of age with an incidence of 1-3%. Most patients with Alzheimer's disease (>95%) have the sporadic form, which is characterized by a late onset (80-90 years of age), and is the consequence of the failure to clear the amyloid-beta (A beta) peptide from the interstices of the brain. A large number of genetic risk factors for sporadic disease have been identified. A small proportion of patients (<1%) have inherited mutations in genes that affect processing of A beta and develop the disease at a much younger age (mean age of similar to 45 years). Detection of the accumulation of A beta is now possible in preclinical and prodromal phases using cerebrospinal fluid biomarkers and PET. Several approved drugs ameliorate some of the symptoms of Alzheimer's disease, but no current interventions can modify the underlying disease mechanisms. Management is focused on the support of the social networks surrounding the patient and the treatment of any co-morbid illnesses, such as cerebrovascular disease.
引用
收藏
页数:18
相关论文
共 179 条
[1]   Which variable is the strongest adjusted predictor of quality of life in caregivers of patients with dementia? [J].
Abdollahpour, Ibrahim ;
Nedjat, Saharnaz ;
Salimi, Yahya ;
Noroozian, Maryam ;
Majdzadeh, Reza .
PSYCHOGERIATRICS, 2015, 15 (01) :51-57
[2]   The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease [J].
Albert, Marilyn S. ;
DeKosky, Steven T. ;
Dickson, Dennis ;
Dubois, Bruno ;
Feldman, Howard H. ;
Fox, Nick C. ;
Gamst, Anthony ;
Holtzman, David M. ;
Jagust, William J. ;
Petersen, Ronald C. ;
Snyder, Peter J. ;
Carrillo, Maria C. ;
Thies, Bill ;
Phelps, Creighton H. .
ALZHEIMERS & DEMENTIA, 2011, 7 (03) :270-279
[3]   Tracking Early Decline in Cognitive Function in Older Individuals at Risk for Alzheimer Disease Dementia The Alzheimer's Disease Cooperative Study Cognitive Function Instrument [J].
Amariglio, Rebecca E. ;
Donohue, Michael C. ;
Marshall, Gad A. ;
Rentz, Dorene M. ;
Salmon, David P. ;
Ferris, Steven H. ;
Karantzoulis, Stella ;
Aisen, Paul S. ;
Sperling, Reisa A. .
JAMA NEUROLOGY, 2015, 72 (04) :446-454
[4]   Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene [J].
Artiga, MJ ;
Bullido, MJ ;
Sastre, I ;
Recuero, M ;
García, MA ;
Aldudo, J ;
Vázquez, J ;
Valdivieso, F .
FEBS LETTERS, 1998, 421 (02) :105-108
[5]   APOE genotype effects on Alzheimer's disease onset and epidemiology [J].
Ashford, JW .
JOURNAL OF MOLECULAR NEUROSCIENCE, 2004, 23 (03) :157-165
[6]  
Australian Bureau of Statistics, 2013, CAUS OF DEATH
[7]   INCIDENCE OF DEMENTIA AND PROBABLE ALZHEIMERS-DISEASE IN A GENERAL-POPULATION - THE FRAMINGHAM-STUDY [J].
BACHMAN, DL ;
WOLF, PA ;
LINN, RT ;
KNOEFEL, JE ;
COBB, JL ;
BELANGER, AJ ;
WHITE, LR ;
DAGOSTINO, RB .
NEUROLOGY, 1993, 43 (03) :515-519
[8]   Apolipoprotein E is essential for amyloid deposition in the APPV717F transgenic mouse model of Alzheimer's disease [J].
Bales, KR ;
Verina, T ;
Cummins, DJ ;
Du, YS ;
Dodel, TC ;
Saura, J ;
Fishman, CE ;
DeLong, CA ;
Piccardo, P ;
Petegnief, V ;
Ghetti, B ;
Paul, SM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (26) :15233-15238
[9]   Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo [J].
Bateman, Randall J. ;
Munsell, Ling Y. ;
Morris, John C. ;
Swarm, Robert ;
Yarasheski, Kevin E. ;
Holtzman, David M. .
NATURE MEDICINE, 2006, 12 (07) :856-861
[10]   Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease [J].
Bateman, Randall J. ;
Xiong, Chengjie ;
Benzinger, Tammie L. S. ;
Fagan, Anne M. ;
Goate, Alison ;
Fox, Nick C. ;
Marcus, Daniel S. ;
Cairns, Nigel J. ;
Xie, Xianyun ;
Blazey, Tyler M. ;
Holtzman, David M. ;
Santacruz, Anna ;
Buckles, Virginia ;
Oliver, Angela ;
Moulder, Krista ;
Aisen, Paul S. ;
Ghetti, Bernardino ;
Klunk, William E. ;
McDade, Eric ;
Martins, Ralph N. ;
Masters, Colin L. ;
Mayeux, Richard ;
Ringman, John M. ;
Rossor, Martin N. ;
Schofield, Peter R. ;
Sperling, Reisa A. ;
Salloway, Stephen ;
Morris, John C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (09) :795-804